Covaxin's Phase-3 Trial Results Out, Claims To Be 77.8% Effective

Hyderabad-based Bharat Biotech has released the phase-3 clinical trial results of "Covaxin" on July 3, claiming it to be 77.8% successful. Moreover, the company said that it provides 63.6% protection to asymptomatic COVID-19 patients and is 65.2% effective against the SARS-CoV-2 & B.1.617.2 Delta variant. The vaccine is said to be 93.4% effective against severe symptomatic cases. As far as safety is concerned, Covaxin's effects are much lower than others.